Corin received FDA 510(k) clearance for its Icona femoral stem implant for total hip arthroplasty (THA). This clearance comes just one month after Corin won FDA clearance for its Unity Knee medial constrained (MC) tibial insert. That implant helps independently stabilize the medial compartment during a standard or robotic-assisted total knee arthroplasty (TKA).
Cirencester, UK-based Corin — which has its U.S. base in Raynham, Massachusetts — designed Icona using comprehensive data from the CorinRegistry. The company says it represents a significant addition to its portfolio of proven implants for THA.
Related: SYNDEO Medical Announces European MDR Approval for Two Product Brands
Corin developed the collared, metaphyseal-filling, triple-taper stem for efficient, reproducible canal preparation and ease of insertion during muscle-sparing approaches. Key features include a reduced proximal lateral shoulder, a swept distal tip and a 15-degree angled insertion feature.
Icona also has reduced shoulder height in smaller sizes, allowing easier insertion around the greater trochanter. The stem’s offset hybrid broaches with combined extraction and compaction tooth geometries preserve anatomy while creating a tapered, press-fit region.
Corin also said Icona has a simple, stackable two-tray system with streamlined instrumentation. Coated with proximal titanium plasma spray and a full calcium phosphate (CaP) layer, it enhances fixation and stability.
The system fully integrates with Corin’s OPSInsight technology as well. OPInsight, a dynamic analysis, optimizes implant position, stability and patient outcomes through preoperative assessments.
“With design features tailored to direct anterior approach (DAA) and streamlined instrumentation for ASCs, Icona reflects the implementation of real-world data in innovation,” said Cynthia Ansari, chief commercial officer at Corin USA. “By leveraging anonymized data from OPSInsight procedures, Corin is able to advance technology and implant design.”
